← Research index · Disorder page · Source YAML

Cross-provider research synthesis

Arsenic Related Cancers

Curated 2026-07-04T00:00:00Z 9 harmonized findings

falcon · 58 citations openscientist · 56 citations

Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Inorganic arsenic in drinking water is an IARC Group 1 human carcinogen, causally linked to a spectrum of malignancies with the best-established sites being skin, lung, and urinary bladder (with kidney/urinary-tract and emerging hepatobiliary/digestive sites).

UNANIMOUS INTEGRATED

epidemiologypathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	iAs in drinking water is IARC Group 1 carcinogen Falcon states the IARC Group 1 classification for drinking-water inorganic arsenic and elsewhere names lung, bladder, and skin as the best-established sites plus kidney and emerging digestive/hepatobiliary sites. DOI:10.1186/s12889-022-14818-x, DOI:10.3390/w15122185
openscientist	CONCORDANT	92%	Epidemiological studies have established a strong association between inorganic arsenic (iAs) exposure in drinking water and an increased incidence of cancer including bladder, liver, lung, prostate, and skin cancer OpenScientist asserts the same Group 1 causal framing and enumerates the cancer sites, adding liver and prostate to the site list. PMID:30223072

Arsenic carcinogenesis is largely non-mutagenic: rather than inducing point mutations it converges on oxidative stress, DNA damage response/repair disruption, chromosomal instability, and epigenetic/epitranscriptomic reprogramming.

UNANIMOUS INTEGRATED

pathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	85%	highlights new molecular mechanisms including noncoding RNAs and m6A RNA modifications; DDR inhibition via ATM/CHEK2 suppression is emphasized Falcon frames arsenic as a multifactorial, largely non-mutagenic carcinogen acting through DDR inhibition (ATM/CHEK2 suppression) and epigenetic/ epitranscriptomic reprogramming.
openscientist	CONCORDANT	90%	Arsenic increases the frequency of micronuclei, chromosome aberrations and sister chromatid exchanges both in humans and in animals, but it does not induce point mutations OpenScientist explicitly states the non-mutagenic, chromosomal-instability mechanism as the distinctive feature of arsenic genotoxicity. PMID:11885915

Inherited variation at the AS3MT locus (10q24.32) governs arsenic methylation efficiency and is the strongest single genetic determinant of inter-individual arsenic-related cancer susceptibility.

UNANIMOUS INTEGRATED

genetic_factor

Provider	Stance	Score	Evidence
falcon	CONCORDANT	70%	with genetic susceptibility (e.g., metabolism efficiency loci near AS3MT) modifying risk Falcon identifies AS3MT metabolism-efficiency loci as the genetic susceptibility modifier but does not enumerate specific variants or GWAS signals.
openscientist	CONCORDANT	92%	AS3MT variation is the strongest single genetic determinant OpenScientist gives the GWAS (P<5x10^-8 at 10q24.32) and specific SNPs (rs3740393, rs11191439) with cancer odds ratios, calling AS3MT the strongest determinant. PMID:22383894, PMID:28640505

Arsenic biotransformation depletes S-adenosylmethionine (SAM), driving DNA methylation dysregulation (global hypomethylation plus tumor-suppressor promoter hypermethylation, e.g. CDKN2A/p16).

MAJORITY INTEGRATED

pathophysiologygene_function

Provider	Stance	Score	Evidence
openscientist	CONCORDANT	92%	Arsenic, a xenobiotic substance, is biotransformed in the body to its methylated species by using the physiological S-adenosyl methionine (SAM). SAM dictates methylation status of the genome and arsenic metabolism leads to depletion of SAM leading to an epigenetic disequilibrium OpenScientist details SAM depletion producing epigenetic disequilibrium and quantifies p16 promoter hypermethylation (42% vs 2%). PMID:25898228, PMID:17479413
falcon	PARTIAL	50%	methylation can consume SAM (methyl donor) influencing epigenetic state Falcon notes that arsenic methylation consumes SAM and influences the epigenetic state, but does not develop the tumor-suppressor promoter hypermethylation detail.

Arsenical skin lesions (raindrop hyperpigmentation and palmoplantar hyperkeratosis/arsenical keratosis) are among the earliest signs of chronic exposure and are precursors to arsenic-induced skin cancers (Bowen disease, SCC, BCC).

UNANIMOUS INTEGRATED

phenotype

Provider	Stance	Score	Evidence
falcon	CONCORDANT	88%	Skin manifestations are repeatedly emphasized as early indicators and precursors of later cancers Falcon frames skin lesions (raindrop hyperpigmentation, palmoplantar hyperkeratosis) as early indicators and precursors of later arsenic-induced cancers.
openscientist	CONCORDANT	90%	hyperpigmentation/depigmentation, hyperkeratosis (arsenical keratoses), and Bowen's disease (squamous cell carcinoma in situ), which may progress to invasive squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) OpenScientist describes the arsenical skin-lesion triad and its progression to invasive SCC and BCC.

Arsenic carcinogenesis has an extraordinarily long latency, with cancer mortality remaining substantially elevated for decades (40+ years) after exposure cessation.

MAJORITY INTEGRATED

prognosis

Provider	Stance	Score	Evidence
openscientist	CONCORDANT	92%	lung and bladder mortality were still greatly elevated (RR = 3.38, 95% confidence interval [CI] = 3.19 to 3.58, P < .001 for lung cancer in men; RR = 4.79, 95% CI = 4.20 to 5.46, P < .001 for bladder cancer in men) OpenScientist quantifies the northern Chile 40-year persistence of lung and bladder cancer mortality after major exposure reduction. PMID:29069505
falcon	PARTIAL	55%	Elevated cancer mortality can persist for decades after exposure cessation Falcon states cancer mortality persists for decades after exposure cessation but does not quantify the 40-year relative risks.

Reducing arsenic exposure through drinking-water mitigation (municipal tap water substitution, filtration) lowers arsenic-related cancer burden, but the benefit accrues slowly over decades because of the long latency.

UNANIMOUS INTEGRATED

treatmentepidemiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	Following municipal water installation in the 1970s, bladder cancer RR in an endemic region declined from ~20 to 5 across cohorts; lung cancer RR declined from ~8 to ~1.5–2, with registry-based analyses spanning 1979–2003 Falcon reports the Taiwan municipal-water intervention with the magnitude of bladder and lung cancer RR declines. DOI:10.1007/s10552-010-9679-2
openscientist	CONCORDANT	85%	Taiwan Blackfoot disease area — tap water installation beginning in the 1960s led to declining cancer gap for birth cohorts born after mitigation OpenScientist reports the same Taiwan mitigation benefit and stresses that full benefit takes decades to materialize. PMID:38461779

Arsenic has a paradoxical dual role: arsenic trioxide is a first-line therapeutic agent for acute promyelocytic leukemia (with ATRA), in contrast to the carcinogenicity of chronic environmental arsenic for solid tumors.

SINGLE LEAD

treatment

Provider	Stance	Score	Evidence
openscientist	CONCORDANT	90%	ATO shows a "dual effect" — carcinogenic for solid tumors but therapeutic for hematologic malignancies; arsenic water exposure was negatively associated with lymphoma and leukemia incidence OpenScientist details arsenic trioxide as first-line APL therapy (with ATRA, 5-year OS >90%) and frames the carcinogen-versus-therapeutic paradox. PMID:40623894, PMID:35570949
falcon	SILENT	—	Falcon's report addresses treatment of arsenic-related solid tumors as standard-of-care and exposure reduction, but does not discuss arsenic trioxide or its therapeutic use in APL.

Tobacco smoking interacts synergistically (more than additively) with arsenic exposure to amplify cancer risk, most notably for lung cancer.

MAJORITY INTEGRATED

comorbidityepidemiology

Provider	Stance	Score	Evidence
openscientist	CONCORDANT	90%	the joint effect from both exposures consistently exceeded the sum of the separate effects by about 70 to 130% OpenScientist quantifies the supra-additive arsenic-tobacco synergism for lung cancer and notes its dose dependence (>100 µg/L). PMID:1554806, PMID:36901176
falcon	PARTIAL	50%	co-exposure increases urinary-tract cancer risk beyond arsenic alone Falcon reports smoking-arsenic co-exposure increasing risk but frames it for urinary-tract cancer and does not quantify the supra-additive lung-cancer synergism.

Narrative

Overview

Both providers frame arsenic-related cancers as a spectrum of malignancies caused by chronic inorganic-arsenic exposure (chiefly via contaminated drinking water), classified as an IARC Group 1 carcinogen, with skin, lung, and bladder as the best-established sites and kidney and hepatobiliary/ digestive sites emerging. Both treat the mechanism as a largely non-mutagenic convergence of oxidative stress, impaired DNA repair, chromosomal instability, and epigenetic reprogramming, gated by inter-individual differences in arsenic methylation. Falcon is a compact, mechanism- and epidemiology-focused report; OpenScientist is a broader, more heavily quantified report with detailed genetics, latency, and treatment coverage.

Agreement

The providers converge on the core biology: IARC Group 1 causal status; the established cancer sites; the non-mutagenic/epigenetic mechanism (SAM depletion, DNA methylation dysregulation, DDR inhibition, chromosomal instability); AS3MT (10q24.32) methylation-efficiency variation as the key susceptibility locus; arsenical skin lesions as early precursors of skin cancer; long latency with persistent post-cessation risk; and the effectiveness (but slow, decades-long payoff) of drinking-water mitigation.

Divergence

OpenScientist adds substantial depth Falcon lacks: specific AS3MT/MTHFR/GSTO variants with odds ratios, the quantified 40-year Chile mortality persistence (lung RR 3.38, bladder RR 4.79), the supra-additive arsenic-tobacco synergism (70-130% excess), chemoprevention (selenium, BEST trial), and the paradoxical therapeutic use of arsenic trioxide in acute promyelocytic leukemia — a topic on which Falcon is silent. Falcon uniquely tabulates site-specific dose-response risk estimates and intervention-technology performance. No genuine contradictions were found; divergences are of coverage, granularity, and framing (e.g., Falcon frames smoking synergism for urinary-tract cancer, OpenScientist for lung cancer).

Integration

The established mechanism, susceptibility, phenotype, latency, and prevention findings (findings 1-7 and 9) reinforce and can refresh the existing Arsenic_Related_Cancers pathophysiology and phenotype nodes (arsenic uptake and metabolism, oxidative stress/DNA damage, epigenetic dysregulation, impaired DNA repair, tumor-suppressor silencing, genomic instability; skin/lung/bladder cancer and arsenical keratosis/hyperpigmentation phenotypes), with OpenScientist supplying quantified AS3MT genetics, latency, and smoking synergism.

Not integrated (leads)

The paradoxical arsenic-trioxide/APL therapeutic dual-role finding is retained as a research lead rather than promoted, since it concerns a distinct hematologic indication rather than the environmental solid-tumor pathophysiology that is the entry's scope. Detailed variant-level odds ratios, chemoprevention trial specifics, and animal-model details remain provider leads pending fetch-reference verification before promotion to curated evidence.

Cross-provider synthesis of two independent deep-research reports (falcon, mechanism/epidemiology-focused; openscientist, comprehensive and heavily quantified). No arsenic-specific disease-level MONDO exists (both reports note this; the kb entry carries only a nested squamous-cell-carcinoma disease_term), so mondo is omitted. best_matching_text values are verbatim excerpts from the cited report bodies; per-provider citations are the identifiers each report leaned on and were not independently fetch-verified in this workspace artifact.